A exploratory analysis of large-scale Phase II clinical trial data published in Nature Medicine on the 16th showed that monoclonal antibody prasinezumab can reduce signs of motor degeneration in patients with rapidly developing Parkinson's disease. There is currently no disease modification therapy for Parkinson's disease, and the characteristic of this neurodegenerative disease is that both motor and non motor symptoms worsen over time. Within the brain α- The aggregation of synaptic nucleoproteins is a characteristic of Parkinson's disease, and multiple preclinical studies have found that this pathological symptom is a key factor driving disease progression. Prasinezumab is the first one designed to work with aggregation α- An experimental therapeutic monoclonal antibody that binds and degrades synaptic nucleoproteins. This antibody was tested in 316 early Parkinson's disease patients in the PASADENA Phase II clinical trial and no substantial impact on disease progression was found. However, the disease progression of the subjects is highly variable. The Roche Research Center team in Basel, Switzerland analyzed the potential effects of four pre designated subgroups with faster progression of motor symptoms in this phase II clinical trial and found that prasinezumab was able to alleviate the decline of motor symptoms in all subgroups with faster progression after 52 weeks of treatment compared to placebo patients. This effect was not observed in the subgroups with slower treatment progression. Researchers suggest that further research is needed to determine whether it is effective after longer treatment courses in patients with slower disease progression. (Lai Xin She)